Sunitinib in combination with capecitabine within its licensed indication for the treatment of advanced and/or metastatic breast cancer
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 March 2009
Topic area
  • Cancer

Cancer reform strategy Batch 5

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC

Project Team

Assessment Group / Evidence Review Group: TBC
Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
5 April 2010 The manufacturer of sunitinib has advised us that regulatory approval for this technology is not being sought at this time following the receipt of trial data. The Institute has therefore decided to remove this appraisal from its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Hall (020 7045 2240 or email: (
23 September 2009 Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid November 2010. The deadline for submissions is expected in approximately early February 2011.

For further information on our processes and methods, please see our CHTE processes and methods manual